Biomedical papers, 2014 (vol. 158), issue 2

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014, 158(2):194-200 | 10.5507/bp.2014.018

Na+/K+-ATPase inhibition by cisplatin and consequences for cisplatin nephrotoxicity

Martin Kubalaa, Jaroslava Geleticovaa, Miroslav Huliciaka, Martina Zatloukalovab, Jan Vacekb, Marek Sebelac
a Department of Biophysics, Centre of the Region Hana for Biotechnological and Agricultural Research, Palacky University Olomouc, Czech Republic
b Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacky University Olomouc
c Department of Protein Biochemistry and Proteomics, Centre of the Region Hana for Biotechnological and Agricultural Research, Palacky University Olomouc

Aims: Cisplatin is a widely used chemotherapeutic. However, it is associated with numerous adverse effects. The aim of our study was examination of cisplatin interaction with Na+/K+-ATPase (NKA, the sodium pump). This enzyme is of crucial importance for all animal cells and particularly for the kidney, which is frequently damaged during chemotherapy.

Methods: The entire NKA was isolated from porcine kidney. Its large cytoplasmic segment connecting transmembrane helices 4 and 5 (C45), was heterologously expressed in E.coli (wild-type or C367S mutant). The ATPase activity was evaluated according to the inorganic phosphate production and the interaction of isolated C45 with cisplatin was studied using chronopotentiometry and mass spectrometry.

Results: Our experiments revealed that cisplatin can inhibit NKA. The finding that other platinum-based drugs with a low nephrotoxicity, carboplatin and oxaliplatin, did not inhibit NKA, suggested that NKA/cisplatin interaction is an important factor in cisplatin adverse effects. The inhibitory effect of cisplatin could be prevented by preincubation of the enzyme with reduced glutathione or DTT. Using chronopotentiometry and mass spectrometry, we found that cisplatin is bound to C45. However, our mutagenesis experiment did not confirm that the suggested Cys367 could be the binding site for cisplatin.

Conclusion: Unintended interactions of drugs present serious limitations to treatment success. Although a large number of membrane pumps have been identified as potential targets of cisplatin, vis-a-vis nephrotoxicity, NKA inhibition seems to be of crucial importance. Experiments with isolated large cytoplasmic segment C45 revealed that it is the main target of cisplatin on NKA and that the reaction with cysteine residues plays an important role in cisplatin/NKA interactions. However, further experiments must be performed to identify the interacting amino acid residues more precisely.

Keywords: cisplatin, Na+/K+-ATPase, nephrotoxicity, adverse effects, glutathione

Received: January 27, 2014; Accepted: April 2, 2014; Prepublished online: April 29, 2014; Published: June 23, 2014


References

  1. Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of cisplatin nephrotoxicity. Toxins 2010;2:2490-18. Go to original source... Go to PubMed...
  2. Safaei R. Role of copper transporters in the uptake and efflux of platinum containing drugs. Cancer Letters 2006;234:34-9. Go to original source... Go to PubMed...
  3. Yonezawa A, Inui K. Organic cation transporter OCT/SLC22A and H(+)/organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents. Biochemical Pharmacology 2011;81:563-8. Go to original source... Go to PubMed...
  4. Rosenberg B. Anti-cancer activity of cis-dichloroammineplatinum(II) and some relevant chemistry. Cancer Treatment Reports 1979;63:1433-8. Go to PubMed...
  5. Barabas K, Milner R, Lurie D, Adin C. Cisplatin: a review of toxicities and therapeutic applications. Veterinary and Comparative Oncology 2008;6:1-18. Go to original source... Go to PubMed...
  6. Ries F, Klastersky J. Nephrotoxicity induced by cancer-chemotherapy with special emphasis on cisplatin toxicity. American Journal of Kidney Diseases 1986;8:368-79. Go to original source... Go to PubMed...
  7. Tsang RY, Al-Fayea T, Au HJ. Cisplatin Overdose Toxicities and Management. Drug Saf 2009;32:1109-22. Go to original source... Go to PubMed...
  8. McWhinney SR, Goldberg RM, McLeod HL. Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther 2009;8:10-6. Go to original source... Go to PubMed...
  9. Vinciguerra M, Mordasini D, Vandewalle A, Feraille E. Hormonal and nonhormonal mechanisms of regulation of the Na,K-pump in collecting duct principal cells. Seminars in Nephrology 2005;25:312-21. Go to original source... Go to PubMed...
  10. Jorgensen PL, Hakansson KO, Karlish SJD. Structure and mechanism of Na,K-ATPase: Functional sites and their interactions. Annu Rev Physiol 2003;65:817-49. Go to original source... Go to PubMed...
  11. Morth JP, Pedersen BP, Toustrup-Jensen MS, Sorensen TLM, Petersen J, Andersen JP, Vilsen B, Nissen P. Crystal structure of the sodium-potassium pump. Nature 2007;450:1043-9. Go to original source... Go to PubMed...
  12. Kubala M, Teisinger J, Ettrich R, Hofbauerova K, Kopecky V, Baumruk V, Krumscheid R, Plasek J, Schoner W, Amler E. Eight amino acids form the ATP recognition site of Na+/K+-ATPase. Biochemistry 2003;42:6446-52. Go to original source... Go to PubMed...
  13. Grycova L, Sklenovsky P, Lansky Z, Janovska M, Otyepka M, Amler E, Teisinger J, Kubala M. ATP and magnesium drive conformational changes of the Na(+)/K(+)-ATPase cytoplasmic headpiece. Biochimica Et Biophysica Acta-Biomembranes 2009;1788:1081-91. Go to original source...
  14. Huliciak M, Vacek J, Sebela M, Orolinova E, Znaleziona J, Havlikova M, Kubala M. Covalent binding of cisplatin impairs the function of Na+/K+-ATPase by binding to its cytoplasmic part. Biochemical Pharmacology 2012;83:1507-13. Go to original source... Go to PubMed...
  15. Dabrowiak DC. Metals in medicine. Wiley 2009
  16. Jorgensen PL. Purification of Na+/K+ATPase - enzyme sources, preparative problems, and preparation from mammalian kidney. Methods in Enzymology 1988;156:29-43. Go to original source... Go to PubMed...
  17. Bradford MM. Rapid and Sensitive Method for Quantitation of Microgram Quantities of Protein Utilizing Principle of Protein-Dye Binding. Analytical Biochemistry 1976;72:248-54. Go to original source... Go to PubMed...
  18. Baginski E, Foa P, Zak B. Determination of phosphorus. Clinical Chemistry 1966;12:546-52.
  19. Trnkova L, Kizek R, Vacek J. Catalytic signal of rabbit liver metallothionein on a mercury electrode: a combination of derivative chronopotentiometry with adsorptive transfer stripping. Bioelectrochemistry 2002;56:57-61. Go to original source... Go to PubMed...
  20. Zatloukalova M, Orolinova E, Kubala M, Hrbac J, Vacek J. Electrochemical Determination of Transmembrane Protein Na+/K+-ATPase and Its Cytoplasmic Loop C45. Electroanalysis 2012;24:1758-65. Go to original source...
  21. Vacek J, Zatloukalova M, Havlikova M, Ulrichova J, Kubala M. Changes in the intrinsic electrocatalytic nature of Na+/K+ ATPase reflect structural changes on ATP-binding: Electrochemical label-free approach. Electrochem Commun 2013;27:104-7. Go to original source...
  22. Dorcak V, Palecek E. Electrochemical Determination of Thioredoxin Redox States. Anal Chem 2009;81:1543-8. Go to original source... Go to PubMed...
  23. Odenheimer B, Wolf W. Reactions of cisplatin with sulfur-containing amino-acids and peptides I. Cysteine and glutathione. Inorg Chim Acta 1982;66:L41-L43. Go to original source...
  24. Hartinger CG, Ang WH, Casini A, Messori L, Keppler BK, Dyson PJ. Mass spectrometric analysis of ubiquitin-platinum interactions of leading anticancer drugs: MALDI versus ESI. Journal of Analytical Atomic Spectrometry 2007;22:960-7. Go to original source...
  25. Zhao T, King FL. Mass-spectrometric characterization of cisplatin binding sites on native and denatured ubiquitin. Journal of Biological Inorganic Chemistry 2011;16:633-9. Go to original source... Go to PubMed...
  26. Daley-Yates PT, McBrien DCH. The inhibition of renal ATPase by cisplatin and some biotransformation products. Chemico-Biological Interactions 1982;40:325-34. Go to original source... Go to PubMed...
  27. Gosland M, Lum B, Schimmelpfennig J, Baker J, Doukas M. Insights into mechanisms of cisplatin resistance and potential for its clinical reversal. Pharmacotherapy 1996;16:16-39. Go to PubMed...
  28. Townsend DM, Deng M, Zhang L, Lapus MG, Hanigan MH. Metabolism of cisplatin to a nephrotoxin in proximal tubule cells. J Am Soc Nephrol 2003;14:1-10. Go to original source... Go to PubMed...
  29. Jones MM, Basinger MA, Holscher MA. Control of the nephrotoxicity of cisplatin by clinically used sulfur-containing-compounds. Fundam Appl Toxicol 1992;18:181-8. Go to original source... Go to PubMed...
  30. Boal AK, Rosenzweig AC. Crystal Structures of Cisplatin Bound to a Human Copper Chaperone. Journal of the American Chemical Society 2009;131:14196-203. Go to original source... Go to PubMed...
  31. Hartinger CG, Tsybin YO, Fuchser J, Dyson PJ. Characterization of platinum anticancer drug protein-binding sites using a top-down mass spectrometric approach. Inorganic Chemistry 2008;47:17-9. Go to original source... Go to PubMed...
  32. Bischin C, Lupan A, Taciuc V, Silaghi-Dumitrescu R. Interactions Between Proteins and Platinum-Containing Anti-Cancer Drugs. Mini-Review in Medicinal Chemistry 2011;11:214-24. Go to original source... Go to PubMed...
  33. Kubala M, Grycova L, Lansky Z, Sklenovsky P, Janovska M, Otyepka M, Teisinger J. Changes in Electrostatic Surface Potential of Na(+)/K(+)-ATPase Cytoplasmic Headpiece Induced by Cytoplasmic Ligand(s) Binding. Biophysical Journal 2009;97:1756-64. Go to original source... Go to PubMed...
  34. Heyrovsky M, Mader P, Vesela V, Fedurco M. The reactions of cystine at mercury-electrodes. Journal of Electroanalytical Chemistry 1994;369:53-70. Go to original source...
  35. Petrushanko IY, Yakushev S, Mitkevich VA, Kamanina YV, Ziganshin RH, Meng XY, Anashkina AA, Makhro A, Lopina OD, Gassman M, Makarov AA, Bogdanova A. S-Glutathionylation of the Na,K-ATPase Catalytic alpha Subunit Is a Determinant of the Enzyme Redox Sensitivity. Journal of Biological Chemistry 2012;287:32195-205. Go to original source... Go to PubMed...
  36. Tian J, Cai T, Yuan ZK, Wang HJ, Liu LJ, Haas M, Maksimova E, Huang XY, Xie ZJ. Binding of Src to Na+/K+-ATPase forms a functional signaling complex. Molecular Biology of the Cell 2006;17:317-26. Go to PubMed...
  37. Li ZC, Cai T, Tian J, Xie JX, Zhao XC, Liu LJ, Shapiro JI, Xie ZJ. NaKtide, a Na/K-ATPase-derived Peptide Src Inhibitor, Antagonizes Ouabain-activated Signal Transduction in Cultured Cells. Journal of Biological Chemistry 2009;284:21066-76. Go to original source... Go to PubMed...
  38. Bhatnagar V, Ramalah A. Characterization of Mg2+-ATPase activity in isolated B16 murine melanoma melanosomes. Mol Cell Biochem 1998;189:99-106. Go to original source... Go to PubMed...
  39. Shiraishi Y, Nagai J, Murakami T, Takano M. Effect of cisplatin on H+ transport by H+-ATPase and Na+/H+ exchanger in rat renal brush-border membrane. Life Sci 2000;67:1047-58. Go to original source... Go to PubMed...